Simplex Trading, LLC Protagonist Therapeutics, Inc Transaction History

Simplex Trading, LLC

$156 Billion
Q1 2025

A detailed history of Simplex Trading, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Simplex Trading, LLC holds 25,934 shares of PTGX stock, worth $1.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

25,934

Previous 5,487 372.64%

Holding current value

$1.38 Million

Previous $211,000 494.31%

% of portfolio

0.0%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$35.09 - $59.76 $717,485 - $1.22 Million	20,447 Added 372.64%	25,934 $1.25 Million
Q4 2024 Feb 11, 2025	BUY	$38.51 - $48.43 $211,304 - $265,735	5,487 New	5,487 $211,000
Q1 2024 Apr 25, 2024	SELL	$21.79 - $32.15 $12,725 - $18,775	-584 Reduced 20.61%	2,250 $65,000
Q4 2023 Feb 02, 2024	BUY	$14.05 - $23.44 $39,817 - $66,428	2,834 New	2,834 $64,000
Q2 2023 Aug 04, 2023	SELL	$18.02 - $29.36 $681,966 - $1.11 Million	-37,845 Reduced 60.02%	25,214 $696,000
Q1 2023 Apr 27, 2023	BUY	$10.78 - $25.38 $679,776 - $1.6 Million	63,059 New	63,059 $1.45 Million
Q3 2022 Nov 04, 2022	SELL	$7.86 - $11.71 $69,812 - $104,008	-8,882 Reduced 92.17%	755 $6,000
Q2 2022 Aug 03, 2022	BUY	$7.06 - $25.52 $32,934 - $119,050	4,665 Added 93.83%	9,637 $76,000
Q1 2022 May 02, 2022	BUY	$23.34 - $36.08 $73,941 - $114,301	3,168 Added 175.61%	4,972 $117,000
Q4 2021 Feb 23, 2022	BUY	$17.63 - $37.1 $31,804 - $66,928	1,804 New	1,804 $61,000
Q1 2021 Apr 26, 2021	SELL	$19.02 - $31.15 $17,954 - $29,405	-944 Closed	0 $0
Q4 2020 Feb 02, 2021	BUY	$18.49 - $25.13 $17,454 - $23,722	944 New	944 $19,000

Others Institutions Holding PTGX

# of Institutions

299

Shares Held

61.3M

Call Options Held

1.01M

Put Options Held

555K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.61B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.

Account

Simplex Trading, LLC Protagonist Therapeutics, Inc Transaction History